-

INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action Lawsuit Against Genius Brands International, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of those who acquired Genius Brands International, Inc. (“Genius” or the “Company”) (NASDAQ: GNUS) securities during the period from March 17, 2020 through July 5, 2020, (the “Class Period”). Investors have until October 19, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The complaint alleges that Defendants violated provisions of the Exchange Act by making false and misleading statements concerning Genius’s Rainbow Rangers intellectual property, the Kartoon Channel! app that Genius launched in June of 2020, as well as its joint venture relating to intellectual property associated with Marvel creator Stan Lee. On July 6, 2020, after Genius announced the creation of a joint venture with POW! Entertainment regarding the intellectual property Stan Lee created following his tenure at Marvel Entertainment, Genius’s share price declined over 25% to close at $2.66 per share.

If you acquired Genius securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq., (212) 371-6600
investigations@kmllp.com
www.kmllp.com

Kirby McInerney LLP

NASDAQ:GNUS

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq., (212) 371-6600
investigations@kmllp.com
www.kmllp.com

Social Media Profiles
More News From Kirby McInerney LLP

JEFFERIES FINANCIAL GROUP, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Jefferies Financial Group, Inc. (“Jefferies” or the “Company”) (NYSE:JEF). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On June 25, 2026, Jefferies reported quarterly results showing weaker asset-management fees a...

ALIGNMENT HEALTHCARE, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (NASDAQ:ALHC). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On July 8, 2026, it was reported that a former executive at Alignment Healthcare fil...

UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On June 30, 2026, Unicycive announced that the FDA had issued a second Complete Response Letter (“CRL”) reg...
Back to Newsroom